论文部分内容阅读
既往因为β受体阻滞剂有负性肌力作用,长期禁用于充血性心力衰竭(CHF).近年来随着研究的深入,认为β受体阻滞剂对衰竭的心肌有利,因此应用β阻滞剂治疗CHF日益受到重视.我院从1989年开始用阿替洛尔(Atenolol)治疗各种病因的慢性CHF,现将其中严重CHF40例的疗效观察报道如下.1 资料及方法1.1 一般资料 40例中男28例,女12例,年龄37～68岁,平均54.6岁.均为住院病人,经常规抗心衰治疗(包括病因治疗,应用洋地黄、利尿剂、血管扩张剂)1～2周后无效.心功能按1964年NYHA分级标准,Ⅲ级23例.Ⅳ级17例.原发病为风心病8例,高心病8例,冠心病8例,肺心病6例,扩张性心肌病6例,糖尿病心肌病2例,甲亢
In the past because β-blockers have negative inotropic effect, long-term banned in patients with congestive heart failure (CHF) .In recent years with the in-depth study, that β-blockers on the failure of myocardial damage, the application of β Blockers treatment of CHF is increasingly valued in our hospital from 1989 on the use of Atenolol (atenolol) for the treatment of various causes of chronic CHF, including severe CHF40 cases were reported as follows.1 Materials and Methods 1.1 General Information 40 cases of male 28 cases, female 12 cases, aged 37 to 68 years old, average 54.6 years old.All inpatients, routine anti-heart failure treatment (including etiological treatment, the application of digitalis, diuretics, vasodilators) 2 weeks after the invalid heart function according to NYHA classification in 1964. Grade Ⅲ 23 cases.Ⅳ grade 17. The primary disease was rheumatic heart disease in 8 cases, 8 cases of high heart disease, coronary heart disease in 8 cases, 6 cases of pulmonary heart disease, dilatation 6 cases of cardiomyopathy, 2 cases of diabetic cardiomyopathy, hyperthyroidism